Home GPCR & G Protein Vasopressin Receptor antagonist Conivaptan HCl For research use only.

Conivaptan HCl

Synonyms: YM 087

Conivaptan HCl(YM 087) is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia.

Conivaptan HCl Chemical Structure

Conivaptan HCl Chemical Structure

CAS No. 168626-94-6

Purity & Quality Control

Batch: S211601 DMSO]107 mg/mL]false]Ethanol]7 mg/mL]false]Water]Insoluble]false Purity: 99.92%
99.92

Conivaptan HCl Related Products

Signaling Pathway

Vasopressin Receptor Signaling Pathways

Vasopressin Receptor Signaling Pathway

Biological Activity

Description Conivaptan HCl(YM 087) is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia.
Targets
Vasopressin receptor 1 [1] Vasopressin receptor 2 [1]
In Vivo
In vivo

Conivaptan (0.03, 0.1 and 0.3 mg/kg i.v.) dose-dependently increases urine volume and reduces urine osmolality in both myocardial infarction and sham-operated rats. Conivaptan (0.3 mg/kg i.v.) significantly reduces right ventricular systolic pressure, left ventricular end-diastolic pressure, lung/body weight and right atrial pressure in myocardial infarction rats. Conivaptan (0.3 mg/kg i.v.) significantly increases dP/dt(max)/left ventricular pressure in myocardial infarction rats. [1] Conivaptan produces an acute increase in urine volume (UV), a reduction in osmolality (UOsm) and, at the end of the investigation, cirrhotic rats receiving the V(1a)/V(2)-AVP receptor antagonist does not show hyponatremia or hypoosmolality. Conivaptan also normalizes U(Na)V without affecting creatinine clearance and arterial pressure. [2] Conivaptan (0.01 to 0.1 mg/kg i.v.) exerts a dose-dependent diuretic effect in dogs without an increase in the urinary excretion of electrolytes, inhibits the pressor effect of exogenous vasopressin in a dose-dependent manner (0.003 to 0.1 mg/kg i.v.) and, at the highest dose (0.1 mg/kg i.v.), almost completely blocks vasoconstriction caused by exogenous vasopressin. Conivaptan (0.1 mg/kg i.v.) improves cardiac function, as evidenced by significant increases in left ventricular dP/dtmax, cardiac output and stroke volume, and reduces preload and afterload, as evidenced by significant decreases in left ventricular end-diastolic pressure and total peripheral vascular resistance in dogs with congestive heart failure. [3]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03000283 Completed
Cerebral Hemorrhage|Cerebral Edema|Intracerebral Hemorrhage|Stroke
Jesse Corry|Allina Health System
 March 22 2017 Phase 1
NCT01370148 Completed
Liver Disease
Cumberland Pharmaceuticals
 April 2011 Phase 1
NCT00887627 Completed
Kidney Diseases|Hyponatremia
Cumberland Pharmaceuticals
 April 2009 Phase 1
NCT00851227 Completed
Liver Disease|Hyponatremia
Cumberland Pharmaceuticals
 February 2009 Phase 1

Chemical Information & Solubility

Molecular Weight 535.04 Formula

C32H26N4O2.HCl
CAS No. 168626-94-6 SDF Download Conivaptan HCl SDF
Smiles CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6.Cl
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 107 mg/mL ( (199.98 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 7 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Conivaptan HCl | Conivaptan HCl supplier | purchase Conivaptan HCl | Conivaptan HCl cost | Conivaptan HCl manufacturer | order Conivaptan HCl | Conivaptan HCl distributor